Adding omalizumab to guideline recommended care may be cost effective in patients with severe allergic asthma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1560, 2006-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Omalizumab for severe allergic asthma: cost effective all round?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Omalizumab is an effective add-on therapy in moderate-to-severe allergic asthma

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 21, Iss. 7, 2005-07 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Omalizumab effective in allergic asthma and allergic rhinitis

Inpharma, Vol. 1, Iss. 1408, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years: A NICE Single Technology Appraisal

By Burch Jane

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 991-1004

Adis International

Access to resources Recommend Favorite

The allergic asthma drug omalizumab [`Xolair'; Genentech/Novartis] is expected to cost an average $US10 000 annually when it is launched

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 418, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite